The first study comparing surgery to active monitoring as treatment for ductal carcinoma in situ (DCIS) finds women who carefully monitor the precancerous cells are no more likely to develop breast ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced that Laura J. Esserman, MD ...

Dr. Schwartz answers the question: 'Difference between in situ breast cancers?' — -- Question: What is the difference between ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)?

Please provide your email address to receive an email when new articles are posted on . Researchers have developed an AI model capable of using an inexpensive, easy-to-obtain chromatin image to ...

Please provide your email address to receive an email when new articles are posted on . Results showed a lower 2-year cumulative rate of invasive ipsilateral breast cancer among patients assigned ...

FRIDAY, Dec. 13, 2024 (HealthDay News) -- For patients with ductal carcinoma in situ (DCIS), active monitoring (AM) is noninferior to guideline-concordant care (GCC) that involves surgery with or ...

Each year, more than 56,500 women are diagnosed with ductal carcinoma in situ (DCIS), a non-invasive type of breast cancer commonly referred to as Stage 0 breast cancer. A woman with DCIS is typically ...

A cancer diagnosis often comes with overwhelming emotions and a flood of unfamiliar medical terms that can spark even more fear. But understanding these terms can help you feel more in control of your ...

There was no significant association between circulating levels of serum 25-hydroxyvitamin D (25[OH]D) and the risk of ductal carcinoma in situ (DCIS) of the breast, either overall or by menopausal ...

Mar. 24 -- TUESDAY, Feb. 12 (HealthDay News) -- Many women diagnosed with a precancerous breast lesion known as ductal carcinoma in situ (DCIS) are highly anxious about their prognosis, even though ...